Lund University is one of the foremost universities in Europe. Here, tradition combines with dynamic development and cutting edge qualifications. Our extensive activities cover education, research and innovation in the areas of technology, science, law, social sciences, economics, medicine, humanities, theology, art, music and theatre. Over 50 000 students study at the university, which has 6 000 employees, mainly in Lund, Malmö and Helsingborg. The university is an elected member of two prominent international networks, the League of European Research Universities (LERU) and Universitas 21. We have agreements with over 600 partner universities in about fifty countries around the world.
Our research group is associated with BioCARE, which is a governmental supported strategic cancer research program shared between universities of Lund and Gothenburg. The overall aim is to promote research of highest international standard and to facilitate the translation of acquired knowledge to Society – in the case of BioCARE, Health Care and Industry are the natural partners.
Applications are invited for a post-doctoral position from researchers with appropriate training and publication-documented expertise. The successful applicant will investigate role of various inhibitors of complement in cancer, which is an ongoing project in a dynamic research group led by prof Anna Blom. The group studies important part of innate immunity, the complement system and its inhibitors, in physiology and pathology. The project will be focused on a newly identified protein with no annotated function, which appears to act as complement inhibitor. Several genetic studies implicate involvement of the protein in cancer.
Applicants should be highly motivated, independent, communicative and inventive. Particularly valuable experience: cancer research, immunology, cell biology, recombinant DNA manipulations, protein expression and analysis, real-time PCR, siRNA, flow cytometry. Applicants must have completed their PhD in biochemistry, molecular biology, immunology, or related discipline by the start of the appointment and preferably within the last 5 years.
Applicants should submit by e-mail (anna.blom@med.lu.se) curriculum vitae including publication list and e-mail address of two references at latest March 10th 2011.
Starting date is flexible and the postdoctoral training supported by tax-free stipend approx 1900 euro/month. The position is funded for 2 years in the first instance and may, subject to satisfactory performance and availability of funds, be extended.
Location: Lund University and Skåne University Hospital; Clinical Research Centre Malmö, Sweden
Group homepage:
Please notice that knowledge of Swedish is not necessary as the majority of Swedes can communicate in English.
Selected publications from the group
Leffler J., Herbert A.P., Norström E., Schmidt Q. C., Barlow P., Blom A. M. and Martin M. (2010) Annexin-II and DNA serve as Factor H ligands on the surface of apoptotic cells., J. Biol. Chem, 285, 3766-76.
Potempa M., Potempa J., Kantyka T., Nguyen K., Wawrzonek K., Manandhar S., Popadiak K., Riesbeck K., Eick S. and Blom A. M. (2009) Interpain, cysteine proteinase from Prevotella intermedia inhibits complement by degrading complement factor C3., PLOS Pathogens, 5, e1000316
Trouw L., Nilsson S., Goncalvez I., Landberg G. and Blom A. M. (2005) C4b-binding protein binds to necrotic cells and DNA, which limits DNA release and inhibits complement activation., J. Exp. Med., 201, 1937-1948.
